Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

4.78EUR
24 May 2019
Change (% chg)

€0.09 (+1.81%)
Prev Close
€4.69
Open
€4.82
Day's High
€4.86
Day's Low
€4.70
Volume
23,552
Avg. Vol
63,961
52-wk High
€8.99
52-wk Low
€4.36

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €275.62
Shares Outstanding(Mil.): 29.17
Dividend: --
Yield (%): --

Financials

  NCOX.PA Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -0.24 -- --
ROI: -5.13 14.23 13.82
ROE: -6.82 15.46 15.24

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

17 Dec 2018

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive license agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

17 Dec 2018

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS, Dec 17 French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

17 Dec 2018

Earnings vs. Estimates